Clinical trials: Dementia, Mild
Alzheimer Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-2214 in adults with mild cognitive impairment or mild-to-moderate Alzheimer's Disease.
- Trial name
- NCT05466422
- Testing
- MK-2214
- Where
- 12 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older.
- Trial name
- NCT01466088
- Testing
- Donepezil, AZD3480
- Where
- 33 sites in United States, Czechia and 3 more
- Volunteers
- 386 people
- Sponsor
- Targacept Inc.
Alzheimer Disease
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
- Trial name
- NCT00141661
- Testing
- PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pfizer
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
- Trial name
- CELIA (NCT05399888)
- Testing
- Diranersen
- Where
- 138 sites in United States, Australia and 15 more
- Volunteers
- 416 people
- Sponsor
- Biogen
Alzheimer Disease, Cognitive Impairment
Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium…
- Trial name
- NCT01453569
- Testing
- Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg
- Where
- 24 sites in China
- Volunteers
- 255 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimer's Disease, Mild Cognitive Impairment
Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures
Alzheimer's disease (AD) clinically characterized by the cognitive impairment and lowering of various functional abilities lead to staggering costs and suffering, which are particularly related to the social impacts of caring for…
- Trial name
- DNS (NCT05153941)
- Where
- Greece
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer's Disease
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
The purpose of the study is to evaluate safety and the pharmacodynamic effects of BMS-241027 on cerebrospinal fluid (CSF) Tau, connectivity magnetic resonance imaging (MRI), and computerized cognitive tests in mild Alzheimer's…
- Trial name
- NCT01492374
- Testing
- BMS-241027
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00112073
- Testing
- bapineuzumab
- Where
- 26 sites in United States
- Volunteers
- 234 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Trial name
- EARS (NCT04928690)
- Volunteers
- 140 people
- Sponsor
- Novoic Limited
Alzheimers Disease
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population)…
- Trial name
- NCT07864623
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Eisai Inc.
Healthy, Alzheimer Disease
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
Up to 20 subjects will receive an injection with [11C]-UCB-J followed by a PET scan on Days 1 and 28
- Trial name
- NCT03577262
- Testing
- [11C]-UCB-J
- Where
- 3 sites in Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
Alzheimer's Disease
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a…
- Trial name
- NCT00810147
- Testing
- BMS-708163
- Where
- 41 sites in United States, Denmark and 2 more
- Volunteers
- 209 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.
- Trial name
- NCT01850238
- Testing
- AADvac1
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Axon Neuroscience SE
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
[18F]APN-1607 PET in Subjects With AD Compared to HC
The overall objective of this study is to compare the overall pattern of [18F]APN-1607 uptake in subjects with MCI, subjects with AD dementia, and healthy subjects.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
- Trial name
- NCT05542953
- Testing
- [18F]APN-1607
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- APRINOIA Therapeutics
Alzheimer's Disease
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.
- Trial name
- NCT00151502
- Testing
- Atorvastatin
- Where
- 99 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Alzheimer's Disease
Effect of NeuroAD on Alzheimer Patients
Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.
- Trial name
- NCT01825317
- Testing
- NeuroAD
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Neuronix Ltd
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Engagement, Patient, Quality of Life
SimpleC Wellness Platform With Social Robot Interaction (Long-term)
This study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Quality of Life, Mood, Aging Well
- Trial name
- NCT05599503
- Testing
- Behavioral Interventions, Robot Interventions
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- SimpleC, LLC